Exact Sciences: Q3 Sell-Off May Be Unjustified, But Long-Term Outlook A Concern
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
The Journal Times5d
Exact Sciences: Q3 Earnings Snapshot
(AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based company said it had a loss of 21 cents.
Madison.com6d
Madison-based Exact Sciences reports Q3 results short of analysts’ expectations
Madison-based Exact Sciences Corp. on Tuesday reported third-quarter results worse than analysts expected. The biomedical giant best known for its Cologuard at-home colon cancer screening test ...
Dr. Zorba Paster: Choose the colon cancer test that works for you
Let’s start with the cheapest, the yearly FIT, or fecal immunochemical test, which looks for fecal blood that might be caused ...
Will Luke Fickell make staff changes? Why can’t the Badgers develop a QB? Wisconsin mailbag
Is it fair to compare the start of the Fickell era to Barry Alvarez's first few years with the Badgers? Why isn't Cade ...
Yahoo Finance5d
Exact Sciences’ forecast cut shocks analysts
Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth ...
Exact Sciences: Long-Term Growth Prospects Intact Despite Short-Term Challenges
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...
Exact Sciences (EXAS) Receives a Buy from Craig-Hallum
In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on Exact Sciences (EXAS – Research Report), with a ...
Morningstar5d
Exact Sciences Corp EXAS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...